2Mosca L,American Heart Association.Hormone replacement therapy andcardiovascular disease:a statement for health care professionalsfrom the American Heart Association[J].Circulation, 2001,104(4) :499.
3Archer DF. Efficacy and tolerability of local estrogen therapy foruro- genital aa-ophy [J]. Menopause, 2010, 17(1): 194-203.
4Nijland EA, Weijmar Schultz WC, Nathorst-Boos J, et al. Tibolone and tmnsdermal E2/NETA for the treatment of female sexual dys- function in naturally menopausal women: results of a randomized active-controlled trial [J]. J Sex Med, 2008, 5(3): 646-656.
5Utian WH, Archer DF, Bachrnann GA, et al. Estrogen and progesto- gen use in postmenopausal women: July 2008 position statement of The North American [J]. Menopause, 2008, 15(4): 584-602.
7Corrao G, Zambonl A, Conti V, et al. Menopause hormone replace- merit therapy and cancer risk and Italian record linkage investiga- tion [J]. Annals of Oncology, 2008, 19(1): 150-155.
8Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women [J]. The New England Journal of Medicine, 2008, 359(7): 697-708.
9Whitney CW, Brunetto VL, Zaino RJ, et al.Phase II study of me- droxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma A gynecologic oncology group study [J]. Gynccol Oncol, 2004, 91: 10-14.
10Mcrch LS, Lckkegaard E, Andreasen AH, et al. Hormone therapy and ovarian cancer [J]. JAMA, 2009, 302(3): 298-305.
